The analysis of CTG and CTA expression in malignant tumors described in this review has been showed that different types of tumors are significantly different from each other according to the frequency of CTA mRNA expression. Melanoma, ovarian cancer and lung cancer have a very high frequency of CTA expression. Lymphoma, kidney cancer, pancreatic cancer have a low frequency of CTA expression. Breast cancer, bladder cancer, prostate cancer demonstrate an intermediate level of CTA expression. High degree malignant tumors in late clinical stage with metastases showed a greater incidence of CTA -gene expression. CTA-genes are expressed together in tumor. If the tumor is positive for one CTA-gene then the expression of several genes is possible. Immunogenic CTA-s are a well object for anti-tumor vaccines creating.

Previous studies have shown that aranosa-lio initiate cell death by activation of CD95-receptor of apoptosis. The mechanism of liposomal aranosa action is still unknown. Anticancer drugs may cause tumor cell death by the activation of autophagy. The purpose of this study was to determine the influence of liposomal aranosa on autophagy. The study was assessed on human melanoma cell lines mel Mtp, mel Ibr, mel Kor, mel Z and mel Mtp clone X. The cells were treated with aranosa-lio or liposomal aranosa at concentration 450 μg/ml for 24 hours. The expression of autophagy were analyzed the expression of mRNA Beclin 1. Expression of mRNA Beclin 1 was reduced on the majority of cell lines, which might be due to the fact that the liposomal form of the drug caused cell death by intrinsic apoptosis which is suppose to suppress autophagy.